purdue sackler 7 4 billion opioid settlement goes into effect

The settlement resolves nearly a decade of litigation against Purdue Pharma and the Sackler family over their role in the opioid crisis. The commercial mechanism is regulatory/legal: Purdue's operations are transferred to a new entity (Knoa Pharma) with monitoring, and the Sacklers are permanently barred from U.S. opioid sales. This reduces future opioid supply and increases compliance costs for the industry. The impact is U.S.-specific, affecting opioid manufacturers and distributors. No direct impact on other pharmaceutical products or margins is specified.